Skip to main content
Log in

Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen

  • Review Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

An urgent need exists to develop a more sophisticated screening system in order to improve diagnostic accuracy of clinically significant cancer and also to reduce the drawbacks of prostate-specific antigen (PSA) screening including overdetection and overtreatment. The most promising next-generation PSA test, which can improve the management of prostate cancer, may be proenzyme PSA (proPSA) or precursor PSA (pPSA). proPSA has pro-leader peptide sequences of seven or less amino acids and previous studies demonstrated that [−2]proPSA, which contains only a 2-amino-acid propeptide leader, could be more useful not only to distinguish between men with and without cancer, but also between tumors with aggressive features with performance exceeding other classical PSA-related indices including ratio of free PSA to total PSA (%f-PSA) and PSA density. Recently, it was demonstrated that baseline [−2]proPSA-related indices were independent factors to predict pathological reclassification at one year or several years after entering active surveillance. Furthermore, a retrospective study suggested that [−2]proPSA might be a useful predictive marker for future developing clinically manifested prostate cancer as well as aggressive tumors. ProPSA-related indices may have the potential for developing a more ideal risk classification for men at risk for prostate cancer, with a screening system maintaining the sensitivity of detecting clinically significant prostate cancer while saving cost, individualized treatment strategies, and follow-up procedures of active surveillance or active treatments. At a minimum, proPSA will be one of the most important new markers on the prostate cancer management in the near future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Nukaga K, Matsuda T, Sobue T (2012) Prediction of the future incidence of cancer in Japan. In: Sobue T, Katanoda K, Ajiki W, Tsukuma H, Ioka A (eds) White paper on cancer and statistics 2012 (in Japanese). Shinohara Shuppan Shin-ha, Tokyo, pp 63–81

    Google Scholar 

  2. Schröder FH, Hugosson J, Roobol MJ et al (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981–990

    Article  PubMed  Google Scholar 

  3. Hugosson J, Carlsson S, Aus G et al (2010) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725–732

    Article  PubMed  PubMed Central  Google Scholar 

  4. Mikolajczyk SD, Grauer LS, Millar LS et al (1997) A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50:710–714

    Article  PubMed  CAS  Google Scholar 

  5. Sokoll LJ, Chan DW, Mikolajczyk SD et al (2003) Proenzyme PSA for the early detection of prostate cancer in the 2.5–4.0 ng/ml total PSA range: preliminary analysis. Urology 61:274–276

    Article  PubMed  Google Scholar 

  6. Lövgren J, Rajakoski K, Karp M et al (1997) Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238:549–555

    Article  PubMed  Google Scholar 

  7. Kumar A, Mikolajczyk S, Goel A et al (1997) Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57:3111–3114

    PubMed  CAS  Google Scholar 

  8. Mikolajczyk SD, Marker KM, Miller LS et al (2001) A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61:6958–6963

    PubMed  CAS  Google Scholar 

  9. Mikolajczyk SD, Rittenhouse H (2003) Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 52:86–91

    Article  PubMed  Google Scholar 

  10. Mikolajczyk SD, Catalona WJ, Evans CL et al (2004) Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50:1017–1025

    Article  PubMed  CAS  Google Scholar 

  11. Peter J, Unverzagt C, Krough TN et al (2001) Identification of precursor forms of prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61:957–962

    PubMed  CAS  Google Scholar 

  12. Mikolajczyk SD, Millar LS, Wang TJ et al (2000) “BPSA”, a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55:41–45

    Article  PubMed  CAS  Google Scholar 

  13. Chan TY, Mikolajczyk SD, Lecksell K et al (2003) Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 62:177–181

    Article  PubMed  Google Scholar 

  14. Bangma CH, Wildhagen MF, Yurdakul G et al (2004) The value of (−7, −5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 93:720–724

    Article  PubMed  CAS  Google Scholar 

  15. Lein M, Semjonow A, Graefen M et al (2005) A multicenter clinical trial on the use of (−5, −7) pro prostate specific antigen. J Urol 74:2150–2153

    Article  Google Scholar 

  16. Catalona WJ, Partin AW, Sanda MG et al (2011) A multicenter study of [−2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol 185:1650–1655

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Semjonow A, K¨opke T, Eltze E et al (2010) Pre-analytical in vitro stability of [−2]proPSA in blood and serum. Clin Biochem 43:926–928

    Article  PubMed  CAS  Google Scholar 

  18. Igawa T, Takehara K, Onita T et al (2014) Stability of [−2]Pro-PSA in whole blood and serum: analysis for optimal measurement conditions. J Clin Lab Anal 28:315–319

    Article  PubMed  CAS  Google Scholar 

  19. Catalona WJ, Bartsch G, Rittenhouse HG et al (2003) Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170(6 Pt 1):2181–2185

    Article  PubMed  CAS  Google Scholar 

  20. Sokoll LJ, Wang Y, Feng Z et al (2008) [−2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180:539–543

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  21. Stephan C, Kahrs AM, Cammann H et al (2009) A [−2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 69:198–207

    Article  PubMed  CAS  Google Scholar 

  22. Le BV, Griffin CR, Loeb S et al (2010) [−2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 183:1355–1359

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  23. Jansen FH, van Schaik RH, Kurstjens J et al (2010) Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. Eur Urol 57:921–927

    Article  PubMed  CAS  Google Scholar 

  24. Sokoll LJ, Sanda MG, Feng Z et al (2010) A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [−2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19:1193–1200

    Article  PubMed  PubMed Central  Google Scholar 

  25. Guazzoni G, Nava L, Lazzeri M et al (2011) Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 60:214–222

    Article  PubMed  CAS  Google Scholar 

  26. Lughezzani G, Lazzeri M, Larcher A et al (2012) Development and internal validation of a prostate health index based nomogram for predicting prostate cancer at extended biopsy. J Urol 188:1144–1150

    Article  PubMed  Google Scholar 

  27. Lazzeri M, Briganti A, Scattoni V et al (2012) Serum index test %[−2]proPSA and Prostate Health Index are more accurate than prostate specific antigen and %fPSA in predicting a positive repeat prostate biopsy. J Urol 188:1137–1143

    Article  PubMed  CAS  Google Scholar 

  28. Ferro M, Bruzzese D, Perdonà S et al (2012) Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 413:1274–1278

    Article  PubMed  CAS  Google Scholar 

  29. Lazzeri M, Haese A, de la Taille A et al (2013) Serum isoform [−2] proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2–10 ng/ml: a multicentric European study. Eur Urol 63:986–994

    Article  PubMed  CAS  Google Scholar 

  30. Stephan C, Vincendeau S, Houlgatte A et al (2013) Multicenter evaluation of [−2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. Clin Chem 59:306–314

    Article  PubMed  CAS  Google Scholar 

  31. Lazzeri M, Haese A, Abrate A et al (2013) Clinical performance of serum prostate-specific antigen isoform [−2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project. BJU Int 112:313–321

    Article  PubMed  CAS  Google Scholar 

  32. Stephan C, Jung K, Semjonow A et al (2013) Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [−2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 59:280–288

    Article  PubMed  CAS  Google Scholar 

  33. Scattoni V, Lazzeri M, Lughezzani G et al (2013) Head-to-head comparison of prostate health index and urinary PCA3 for predicting cancer at initial or repeat biopsy. J Urol 190:496–501

    Article  PubMed  Google Scholar 

  34. Perdonà S, Bruzzese D, Ferro M et al (2013) Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 73:227–235

    Article  PubMed  Google Scholar 

  35. Ito K, Miyakubo M, Sekine Y et al (2013) Diagnostic significance of [−2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0–10.0 ng/mL range. World J Urol 31:305–311

    Article  PubMed  Google Scholar 

  36. Ferro M, Bruzzese D, Perdonà S et al (2013) Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2–10 ng/ml. PLoS ONE 8:e67687

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  37. Ng CF, Chiu PK, Lam NY et al (2014) The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL. Int Urol Nephrol 46:711–717

    Article  PubMed  CAS  Google Scholar 

  38. Lughezzani G, Lazzeri M, Haese A et al (2013) Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol (in press). doi:10.1016/j.eururo.2013.12.005

  39. Fossati N, Lazzeri M, Haese A, et al (2014) Clinical performance of serum isoform [−2]proPSA (p2PSA) and its derivatives, namely %p2PSA and PHI (Prostate Health Index) in men younger than 60 years of age: results from a multicentric European study. BJU Int (in press). doi:10.1111/bju.12718

  40. Tosoian JJ, Loeb S, Feng Z et al (2012) Association of [−2] proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol 188:1131–1136

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  41. Hirama H, Sugimoto M, Ito K et al (2014) The impact of baseline [−2] proPSA-related indices on the prediction of pathological reclassification at 1 year during active surveillance for low-risk prostate cancer: the Japanese multicenter study cohort. J Cancer Res Clin Oncol 140:257–263

    Article  PubMed  PubMed Central  Google Scholar 

  42. Heidegger I, Klocker H, Steiner E et al (2014) [−2]proPSA is an early marker for prostate cancer aggressiveness. Prostate Cancer Prostatic Dis 17:70–74

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kazuto Ito.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ito, K., Fujizuka, Y., Ishikura, K. et al. Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen. Int J Clin Oncol 19, 782–792 (2014). https://doi.org/10.1007/s10147-014-0742-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-014-0742-y

Keywords

Navigation